Aerovance focuses on respiratory and allergic disease indications where current therapies are inadequate or non-existent.
Asthma affects roughly 16 million people in the United States. The U.S. market for asthma therapies is estimated at $9 billion, with severe asthma accounting for $2 billion–$4 billion in the United States.
Cystic fibrosis (CF) is a life-threatening, inherited disease that affects around 70,000 people worldwide. The median life expectancy of a CF patient is 35 years. The current market for all CF therapies is approximately $800 million.
Chronic Obstructive Pulmonary Disease (COPD) will rank fifth among medical conditions that impose the most burden on society by 2020, affecting more than 200 million people worldwide.
Eczema is a dermatological manifestation of atopic disease that affects approximately 1-3% of adults worldwide.
Learn more: Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Eczema.
